Related Experiment Video
Updated: Jul 1, 2026

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
Published on: August 3, 2011
Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion
Melissa A Tran1, Raghavendra Gowda, Arati Sharma
1Department of Pharmacology, The Pennsylvania State University, Hershey, Pennsylvania 17033, USA.
Abstract:
Most events promoting early melanoma development are yet to be identified, but deregulation of the B-Raf and Akt3 signaling cascades is an important regulator of this process. Approximately 90% of normal moles and approximately 60% of early invasive cutaneous melanomas contain a T1799A B-Raf mutation ((V600E)B-Raf), leading to 10 times higher enzyme activity and constitutive activation of the mitogen-activated protein kinase pathway. Furthermore, approximately 70% of melanomas have elevated Akt3 signaling due to increased gene copy number and PTEN loss. Therefore, targeting (V600E)B-Raf and Akt3 signaling is necessary to prevent or treat cutaneous melanocytic lesions. Agents specifically targeting these proteins are needed, having fewer side effects than those inhibiting both normal and mutant B-Raf protein or targeting all three Akt isoforms. In this study, a unique nanoliposomal-ultrasound-mediated approach has been developed for delivering small interfering RNA (siRNA) specifically targeting (V600E)B-Raf and Akt3 into melanocytic tumors present in skin to retard melanoma development. Novel cationic nanoliposomes stably encapsulate siRNA targeting (V600E)B-Raf or Akt3, providing protection from degradation and facilitating entry into melanoma cells to decrease expression of these proteins. Low-frequency ultrasound using a lightweight four-cymbal transducer array enables penetration of nanoliposomal-siRNA complex throughout the epidermal and dermal layers of laboratory-generated or animal skin. Nanoliposomal-mediated siRNA targeting of (V600E)B-Raf and Akt3 led to a cooperatively acting approximately 65% decrease in early or invasive cutaneous melanoma compared with inhibition of each singly with negligible associated systemic toxicity. Thus, cationic nanoliposomes loaded with siRNA targeting (V600E)B-Raf and Akt3 provide an effective approach for targeted inhibition of early or invasive cutaneous melanomas.
Insights
This study introduces a novel nanoliposomal-ultrasound method to deliver siRNA targeting B-Raf and Akt3, effectively reducing melanoma development with minimal toxicity.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Melanoma development involves B-Raf and Akt3 signaling pathways.
- Specific mutations like T1799A in B-Raf ((V600E)B-Raf) and elevated Akt3 signaling are common in melanomas.
- Targeted therapies are needed to inhibit these specific pathways with fewer side effects.
Purpose of the Study:
- To develop a novel nanoliposomal-ultrasound delivery system for siRNA targeting (V600E)B-Raf and Akt3.
- To evaluate the efficacy of this approach in reducing melanoma development in skin.
- To assess the safety and systemic toxicity of the targeted delivery system.
Main Methods:
- Utilized cationic nanoliposomes to encapsulate siRNA targeting (V600E)B-Raf or Akt3.
- Employed low-frequency ultrasound for enhanced penetration of the nanoliposomal-siRNA complex into skin layers.
- Administered the treatment to melanocytic tumors in laboratory or animal skin models.
Main Results:
- Nanoliposomal siRNA delivery successfully targeted and reduced the expression of (V600E)B-Raf and Akt3 in melanoma cells.
- Combined targeting of (V600E)B-Raf and Akt3 resulted in a significant, cooperative decrease of approximately 65% in melanoma.
- The treatment exhibited negligible associated systemic toxicity.
Conclusions:
- Cationic nanoliposomes combined with ultrasound offer an effective strategy for targeted siRNA delivery to melanoma.
- This approach provides a promising therapeutic avenue for inhibiting early and invasive cutaneous melanomas.
- The targeted inhibition of (V600E)B-Raf and Akt3 signaling pathways shows potential for melanoma treatment with improved safety profiles.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Experimental RNAi

